BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » Lower levels of apolipoprotein CIII reduce risk of getting type 1 diabetes

Lower levels of apolipoprotein CIII reduce risk of getting type 1 diabetes

 

 

 

 

A promising way to delay onset of type 1 diabetes is to reduce the concentration of apolipoprotein CIII (apoCIII) in blood. This discovery is presented in a newly published article in PNAS from June 2011. It took twice as long for the rats that have undergone therapy reducing apoCIII to develop type 1 diabetes.

Patients suffering from type 1 diabetes have high levels of apoCIII in their blood. Whether apoCIII is a diabetes-inducing factor has so far been unclear.

Researchers in Professor Berggren’s group have worked with rats that have a predisposition to develop a form of type 1 diabetes similar to the disease in humans. Blood tests in these rats show high concentration of apoCIII even before onset of type 1 diabetes. Excessive apoCIII leads to premature death of insulin-producing beta cells.

To reduce beta cell death, concentration of apoCIII can be reduced by a specifically designed so called antisense therapy. Following treatment, rats with predisposition to type 1 diabetes got the disease significantly later; it took twice as long before they got diabetes.

A high concentration of apoCIII is therefore believed to be a diabetes inducing factor. There is a potential to delay the onset of the disease by reducing apoCIII concentration in patients with predisposition to type 1 diabetes.

Read more:

Lowering apolipoprotein CIII delays onset of type 1 diabetes. Holmberg R, Refai E,  Höög A, Crooke RM, Graham M, Olivecrona G, Berggren PO, and Juntti-Berggren L. Proc Natl Acad Sci U S A. 2011 June;108(26):10685-9

February 21, 2012 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved